Dong-A ST, exports ₩3 billion in the first half

First sales performance after launching in Japan at the end of last year

Chong Kun Dang's exports surged by 33%

Dong-A ST's Nesp biosimilar is targeting the Japanese market.

 

After launching the product in the Japanese market at the end of last year, it made exports for the first time in the first half of this year.

 

Chong Kun Dang is also targeting the Japanese market in earnest after launching Nesp biosimilar in the Japanese market around the same time as Dong-A ST.

 

Two domestic biosimilar products increase the possibility of a soft landing in the Japanese market.

 

According to the pharmaceutical industry on the 25th, Dong-A ST is selling a Nesp biosimilar named 'Darbepoetin-α (DA-3880)' in Japan.

 

Dong-A ST obtained an item license for this product in Japan in last September, and started officially launching it from the end of November.

 

Sales in Japan are handled by the local partner, Sanwa Kagaku Kenkyusho (SKK).

 

It exported about ₩3 billion in the first half of this year.

 

An official from Dong-A ST explained, "The amount that Dong-A ST exported to Japan was ₩700 million in the first quarter and ₩2.4 billion in the second quarter." Considering the fact that Dong-A ST's exports to Japan were hardly ever until the end of last year, it is calculated that virtually all of them are Nesp biosimilars.

 

Chong Kun Dang, which entered Japan at the same time as Dong-A ST with the same Nesp biosimilar, also performed well.

 

In the case of Chong Kun Dang, the product was released in December of the same year after obtaining an item permission for Nesp biosimilar 'Nesbell (CKD-11101)' from the Japanese government in September last year.

 

Like Dong-A ST, sales are conducted through local partners.

 

The Japanese subsidiary of the global pharmaceutical company Mylan is in charge of local sales.

 

Chong Kun Dang's exports to Japan in the first half of this year were ₩21.4 billion, an increase of about ₩5.3 billion (32.7%) from ₩16.1 billion in the first half of last year.

 

This is the total amount exported to Japan, including Nesbell.

 

Considering that Chong Kun Dang's semiannual exports to Japan have been around ₩17 billion over the past five years, it is interpreted that such an increase in exports can be viewed as a result of Nesp biosimilars.

 

A Chong Kun Dang official said, "It is difficult to disclose the sales performance of individual items in Japan, but the increase in exports to Japan is due to the even growth of not only Nesbell but also various products." Regarding this, an official from the pharmaceutical industry said, "Since both products are still in the early stages of release, it seems to be positive to enter the Japanese market, and the performance in Japan is expected to improve further." Nesp, the original of the two products, is a second-generation anemia treatment developed jointly by Amgen in the United States and Kyowa Kirin in Japan.

 

It is mainly used for the treatment of anemia in chronic renal transition patients and anemia by chemotherapy.

 

Nesp's global sales are estimated at $3 billion, of which Japan's sales are estimated at ₩560 billion, which is about 15%.